97 related articles for article (PubMed ID: 1006321)
1. [Aspects of the physiologic bioavailability of spironolactone and canrenone].
Portal A; Gaillot J; Bieder A; Rodary C; Bertharion JJ
Sem Hop Ther; 1976 Nov; 52(9):465-70. PubMed ID: 1006321
[No Abstract] [Full Text] [Related]
2. Is canrenone the major metabolite of spironolactone?
Merkus FW
Clin Pharm; 1983; 2(3):209-10. PubMed ID: 6883952
[No Abstract] [Full Text] [Related]
3. Pharmacokinetics of canrenone after oral administration of spironolactone and intravenous injection of canrenoate-K in healthy man.
Krause W; Karras J; Seifert W
Eur J Clin Pharmacol; 1983; 25(4):449-53. PubMed ID: 6653638
[TBL] [Abstract][Full Text] [Related]
4. Application of a simple fluorometric method on absorption of canrenone.
Radó JP; Szende L; Takó J; Nagy O; Kozma C
Int J Clin Pharmacol Biopharm; 1976 Mar; 13(2):123-6. PubMed ID: 1254376
[TBL] [Abstract][Full Text] [Related]
5. Ring D oxygenated Spirolactones. Characterization of human metabolic product of spironolactone.
Chinn LJ; Brown EA; Mizuba SS; Karim A
J Med Chem; 1977 Mar; 20(3):352-5. PubMed ID: 845867
[TBL] [Abstract][Full Text] [Related]
6. Validation of plasma and urinary canrenone for determination of bioavailability of spironolactone--comparison of tablets with solution/suspension.
Tidd MJ; Ramsay LE; Shelton JR; Palmer RF
Int J Clin Pharmacol Biopharm; 1977 May; 15(5):205-10. PubMed ID: 873663
[TBL] [Abstract][Full Text] [Related]
7. The influence of age and multimorbidity on the pharmacokinetics and metabolism of spironolactone.
Platt D; Abshagen U; Mühlberg W; Horn HJ; Schmitt-Rüth R; Vollmar J
Arch Gerontol Geriatr; 1984 Jul; 3(2):147-59. PubMed ID: 6476975
[TBL] [Abstract][Full Text] [Related]
8. Enhancement by food of canrenone bioavailability from spironolactone.
Melander A; Danielson K; Scherstén B; Thulin T; Wåhlin E
Clin Pharmacol Ther; 1977 Jul; 22(1):100-3. PubMed ID: 872489
[TBL] [Abstract][Full Text] [Related]
9. [Intersubject comparison of the bioavailability of spironolactone in 2 pharmaceutical dosage forms].
Lucchelli PD; Monarca A; Del Mastro S; Sega R
Boll Chim Farm; 1978 Aug; 117(8):487-95. PubMed ID: 743391
[No Abstract] [Full Text] [Related]
10. Pharmacokinetics of canrenone and metabolites after base hydrolysis following single and multiple dose oral administration of spironolactone.
Ho PC; Bourne DW; Triggs EJ; Heazlewood V
Eur J Clin Pharmacol; 1984; 27(4):441-6. PubMed ID: 6519151
[TBL] [Abstract][Full Text] [Related]
11. [Comparative study of relative biovailability of several spironolactone formulations in a steady-state test (author's transl)].
Rosenthal J; Jaeger H; Specker M
Arzneimittelforschung; 1979; 29(9):1428-32. PubMed ID: 583254
[TBL] [Abstract][Full Text] [Related]
12. The metabolism of canrenone in vitro by rat liver preparations.
Boreham DR; Vose CW; Palmer RF; Slater TF; Cheeseman K
Xenobiotica; 1981 Apr; 11(4):231-40. PubMed ID: 7303717
[TBL] [Abstract][Full Text] [Related]
13. Effect of neomycin on the bioavailability of spironolactone: a single-dose study.
Bartle WR; Coates PE; Fisher MM; Louman FJ
Am J Hosp Pharm; 1979 Dec; 36(12):1701-3. PubMed ID: 525647
[TBL] [Abstract][Full Text] [Related]
14. Spironolactone response related to plasma canrenone concentration [proceedings].
Hettiarachchi J; Ramsay LE
Br J Clin Pharmacol; 1979 Apr; 7(4):426P-427P. PubMed ID: 444376
[No Abstract] [Full Text] [Related]
15. Effect of micronization on the bioavailability and pharmacologic activity of spironolactone.
McInnes GT; Asbury MJ; Ramsay LE; Shelton JR; Harrison IR
J Clin Pharmacol; 1982; 22(8-9):410-7. PubMed ID: 7130430
[TBL] [Abstract][Full Text] [Related]
16. Paradoxical reversal of the suppressed potassium secretion during treatment with combinations of antikaluretic agents (spironolactone, canrenone, triamterene, amiloride); a possible site of action in Henle's loop.
Radó JP; Sawinsky I; Juhos E
Horm Metab Res; 1976 May; 8(3):250-1. PubMed ID: 939474
[No Abstract] [Full Text] [Related]
17. Influence of food on the bioavailability of spironolactone.
Overdiek HW; Merkus FW
Clin Pharmacol Ther; 1986 Nov; 40(5):531-6. PubMed ID: 3769384
[TBL] [Abstract][Full Text] [Related]
18. Determination of canrenone, the major metabolite of spironolactone, in plasma and urine by high-performance liquid chromatography.
Krause W; Karras J; Jakobs U
J Chromatogr; 1983 Oct; 277():191-9. PubMed ID: 6643605
[TBL] [Abstract][Full Text] [Related]
19. [Bioavailability studies of two spironolactone-preparations (author's transl)].
Vergin H; Nuss U; Schwarzländer F; Strobel K; Weigand W; Hitzenberger G
Arzneimittelforschung; 1981; 31(9):1498-503. PubMed ID: 7197963
[TBL] [Abstract][Full Text] [Related]
20. Species differences in the metabolism and disposition of spironolactone.
Karim A; Kook C; Zitzewitz DJ; Zagarella J; Doherty M; Campion J
Drug Metab Dispos; 1976; 4(6):547-55. PubMed ID: 11976
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
